
Yu Tao
University of North Texas Health Science Center
Dr Yu Tao is an M.D. and PhD in integrative physiology. She earned her M.D. from Anhui Medical University, China, and conducted medical training and clinical research in the nephrology department at Renmin Hospital of Wuhan University, China. Subsequently, Dr. Tao pursued her Ph.D. training at the University of North Texas Health Science Center in Dr. Rong Ma's lab. Her research is dedicated to glomerular physiology and pathophysiology in chronic kidney disease, particularly diabetic nephropathy, with the aim of developing more therapeutic strategies for kidney diseases.

Jiaojiao Xu
Johns Hopkins University
Dr. Jiaojiao Xu is a Researcher Associate in the department of Physiology at Johns Hopkins University. She earned her Ph.D. degree from the Chinese University of Hong Kong. She was then moved to Johns Hopkins University for postdoctoral training in Dr. Jennifer Pluznick laboratory. Her research interest is focused on two different aspects of gut microbiome and host interaction: (1) deciphering the influences of gut microbes on glomerular filtration rate in health and disease, and (2) elucidating the novel role of olfactory receptor 558 (OLFR558) that responds to gut microbial metabolites in blood pressure control.
The kidneys play a vital role in maintaining homeostasis by filtering waste products, regulating blood pressure, and producing essential hormones. Chronic kidney disease and, in severe cases, end-stage renal disease (ESRD) are significant public health concerns, with a substantial economic burden on healthcare systems worldwide. Despite the importance of understanding renal pathology and pathophysiology in the disease condition, research in this field has faced challenges.
One major limitation is the complexity of the kidney's structure and function, which involves intricate interactions between various cell types, signaling pathways, and physiological processes. This complexity makes it difficult to untangle the underlying mechanisms of renal diseases and develop effective targeted therapies.
Another limitation is the lack of suitable animal models that accurately recapitulate human renal pathologies. Many animal models fail to fully replicate the pathophysiological features and disease progression observed in humans, hindering the translation of preclinical findings into clinical settings.
Besides, the limited regenerative capacity of kidney tissues has been a barrier to developing regenerative therapies. In addition, the traditional management of ESRD has relied on dialysis and kidney transplantation, which are invasive and costly.
This Methods Collection aims to provide an overview of the latest research and developments in renal pathology, pathophysiology, and disease treatment. It highlights innovative methods and promising therapeutic strategies that address the current limitations in understanding and treating renal diseases.
0 Views
•
2025
•
Melise Oliveira Mariano*1, Maria Theresa Araújo Balby-Rocha*2, Maria Clara Soares Klein2, Bruno Serrano Barbosa1, Marcella Liciani Franco1, Andrei Furlan da Silva1, Jaqueline de Carvalho Arjona1, Gleice Regina Josefi-Rocha1, Stephany Beyerstedt1, Tuany Marques Reiter Alves1, Érika Bevilaqua Rangel1,3
Analyzing Renal and Cloacal Function in Zebrafish
Rebecca Wingert*1
1University of Notre Dame
Targeted Ablation and Regeneration of Renal Macrophages Using ILY and hCD59 in Transgenic Mice: Insights into Kidney Disease and Repair
Xuebin Qin*1
1Division of Comparative Pathology, Tulane National Primate Research Center|Department of Microbiology and Immunology, Tulane University School of Medicine